In a challenging market environment, TNGX stock has reached a new 52-week low, with shares plummeting to $2.58. According to InvestingPro data, while the company maintains strong liquidity with a ...
Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for Tango Therapeutics in a ...
Research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Wednesday, February 5th. Leerink ...
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision ...
Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies are ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
(MENAFN- GlobeNewsWire - Nasdaq) BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering ...
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback